

## INOVIQ APPOINTS GLOBAL EXOSOME AND CELL THERAPY LEADER DR REBECCA LIM AS CHIEF SCIENTIFIC OFFICER

- Dr Rebecca Lim appointed Chief Scientific Officer (CSO), effective 12 January 2026
- Brings over 20 years of experience in exosome science, translational research and clinical development across cell and gene therapy in Australia and the US
- Professor Greg Rice transitions to part-time Founding Scientist & Advisor, providing strategic guidance, diagnostics expertise, thought leadership and chairing the Medical and Scientific Advisory Board

INOVIQ Limited (ASX: IIQ) (**INOVIQ** or the **Company**) is pleased to announce the appointment of Dr Rebecca Lim as Chief Scientific Officer, effective 12 January 2026. Dr Lim will lead INOVIQ's research and development strategy and execution of preclinical research, clinical development and regulatory programs for exosome capture tools, diagnostics and therapeutics. Her focus will be on leading the R&D team to achieve technical, development and regulatory milestones on-time and on-budget, bolstering INOVIQ's position as a global leader in exosome technologies.

Dr Lim, BSc (Hons), PhD, is an internationally recognised biotechnology executive with more than 20 years of experience spanning translational research, clinical development and commercialisation in cell and gene therapy, regenerative medicine, and extracellular vesicle (EV) technologies. She has held senior leadership roles across Asia-Pacific and the United States, most recently as Director of Strategic Alliances at CTMC, a joint venture contract development and manufacturing organisation (CDMO) between MD Anderson Cancer Centre and National Resilience. During her tenure, she led cross functional teams delivering seven advanced therapy programs from preclinical through IND clearance and GMP manufacturing. Previous roles include SVP Scientific Affairs at Prescient Therapeutics (ASX:PTX), Scientific Director of Cell Therapies and Regenerative Medicine at the Monash Health Translation Precinct, and A/Prof Obstetrics & Gynaecology at Monash University.

Dr Lim has an exceptional track record guiding programs from discovery through IND-enabling studies, including CMC development, process scale-up, and technology transfer from academia and early-stage innovators into regulated development environments. She brings deep expertise in TGA and FDA regulatory pathways and clinical development, having overseen multiple cell and exosome-based therapies through to first-in-human studies. Widely published with over 100 peer-reviewed papers and several granted and provisional exosome patents, Dr Lim is internationally recognised for her scientific contributions to EV and cell therapy innovation. She holds a Bachelor of Science (Hons) in Biomedical Science and Molecular Biology from Murdoch University and a PhD in Medicine & Pharmacology from the University of Western Australia.

**Dr Rebecca Lim commented:** *"I am thrilled to join INOVIQ at this exciting stage of growth. INOVIQ's exosome technologies have transformative potential across diagnostics and therapeutics. I look forward to applying my experience in exosome science, clinical development and regulatory strategy to accelerate INOVIQ's CAR-EV therapeutic program and advance it toward first-in-human studies in 2028. My focus will be on disciplined execution, and on-time, on-budget delivery of programs to position INOVIQ as a global exosome leader."*

**CEO Dr Leearne Hinch said:** *"Rebecca's appointment further strengthens INOVIQ's leadership team as we advance our mission to transform cancer care through next-generation diagnostics and therapeutics. Her deep expertise in exosome science, combined with US experience in CMC, clinical strategy, and alliance management will enhance our R&D capabilities and accelerate progress of our*

*EV therapeutic pipeline. We are delighted to welcome Rebecca to the team and look forward to leveraging her CDMO experience to advance our CAR-EV program into the clinic."*

**Professor Greg Rice added:** *"Rebecca's unique experience and leadership in exosome translational biology, and in both therapeutic and diagnostic applications, will further strengthen and drive INOVIQ's programs toward clinical and commercial outcomes. I am excited to continue supporting the Company in a part-time role as Founding Scientist and Advisor, ensuring continuity of scientific leadership as we enter this next phase of growth. In this role, I will provide strategic guidance on our scientific and innovation priorities, lead our diagnostics efforts, mentor our research teams, represent INOVIQ as an industry thought leader and chair the Company's Medical and Scientific Advisory Board."*

*Authorised for release by Company Secretary, Mark Edwards.*

## FURTHER INFORMATION

### Dr Leearne Hinch

Chief Executive Officer

E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)

M +61 400 414 416

### Peter Gunzburg

Chairman

E [peter.gunzburg@gmail.com](mailto:peter.gunzburg@gmail.com)

M +61 412 927 773

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit [www.inoviq.com](http://www.inoviq.com).